LFCR — LIFECORE BIOMEDICAL, INC. \DE\
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1005286 ·
Last close
$6.52
Market Cap
$246.80M
52W High
$8.98
52W Low
$3.63
ADV30
267,799
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 34,167,000 | 12,075,000 | 2,567,000 | -6,156,000 | 229,500,000 | 17,241,000 | 263,594,000 |
| Mar 2026 | 23,193,000 | 4,462,000 | -4,672,000 | -14,980,000 | 225,499,000 | 20,795,000 | 253,937,000 |
| Sep 2025 | 31,109,000 | 7,791,000 | -3,067,000 | -9,991,000 | 235,204,000 | 18,856,000 | 245,741,000 |
| May 2025 | 36,444,000 | 13,982,000 | 2,899,000 | -1,147,000 | 239,342,000 | 8,265,000 | 238,006,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,008,000
Investing CF
$-3,408,000
Financing CF
$-8,829,000
CapEx
$-10,408,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-244,337,000
Inventory
$25,475,000
Receivables
$38,023,000
ST Investments
—
EBIT TTM
$-4,838,000
Pretax Income TTM
$-31,842,000
Interest Exp TTM
$27,004,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$129,464,592
EBITDA
$8,242,287
Free Cash Flow
—
Enterprise Value
$345,275,616
Total Cash
$17,241,000
Total Debt
$156,375,008
Shares Out
37,853,060
Trailing EPS
$-1.27
Book Value
$-0.90
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | 232,177,000 | 246,379,000 | -14,202,000 | — |
| May 2025 | 128,867,000 | -12,006,000 | -38,717,000 | 239,342,000 | 238,006,000 | 1,336,000 | -206,000 |
| May 2024 | 128,261,000 | -7,188,000 | 12,013,000 | 253,960,000 | 242,645,000 | 11,315,000 | 257,000 |
| May 2023 | 103,269,000 | -19,720,000 | -99,563,000 | 253,545,000 | 257,775,000 | -4,230,000 | -17,441,000 |
| May 2022 | 111,270,000 | -3,432,000 | -116,715,000 | — | — | — | -22,593,000 |
TTM Snapshot
Revenues TTM
$122,099,000
NetIncome TTM
$-51,874,000
OpCashFlow TTM
$0
Assets (Latest)
$232,177,000
Forward EPS
$-0.78
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $6.52 · call volume: 2,540 · put volume: 651
Expected Move to 2026-12-18:
±$1.35
(20.71%) —
implied range
$5.17 –
$7.87
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | $246.15M | $2.60 | — |
| AKBA | Akebia Therapeutics, Inc. | $247.48M | $0.89 | — |
| SIGA | SIGA TECHNOLOGIES INC | $248.60M | $3.46 | — |
| TRDA | Entrada Therapeutics, Inc. | $242.19M | $6.22 | — |
| PYXS | Pyxis Oncology, Inc. | $241.88M | $2.90 | — |
News headlines (Yahoo Finance, 1h cache)
Lifecore Biomedical to be Acquired by Webster Equity Partners
2026-09-28 12:45 · Yahoo
Lifecore Biomedical to Participate at CPHI Global Conference
2026-09-03 20:05 · Yahoo
Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company
2026-09-02 11:05 · Yahoo
Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity
2026-08-17 15:29 · Yahoo
Lifecore Biomedical (LFCR) Q2 2026 Earnings Call Transcript
2026-08-12 15:31 · Yahoo
Lifecore Biomedical Inc (LFCR) (Q2 2026) Earnings Call Highlights: Strategic Wins and Capacity ...
2026-08-05 19:04 · Yahoo
Lifecore Biomedical to Report Financial Results for the Second Quarter Ended June 30, 2026, on August 5, 2026
2026-07-29 20:05 · Yahoo
Lifecore Biomedical Signs Three New Customer Agreements
2026-07-28 11:05 · Yahoo
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-15 20:05 · Yahoo
Lifecore Biomedical Inc (LFCR) Continues Winning Contracts, Ignored by the Market
2026-07-15 13:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.